title: Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
abstract: Following the introduction of rituximab, the long-term overall survival (OS) rate of advanced-stage follicular lymphoma (FL) cases was expected to improve after the introduction of rituximab: however, there is a lack of large-scale survey data in Asia due to the relatively low incidence of FL. We conducted a retrospective survey to assess the treatment outcomes in patients with newly diagnosed advanced-stage FL in 29 institutions in Hokkaido from January 2001 to December 2010. The total number of patients was 443 (men 47.6%, women 52.4%), with a median age of 55 years (range 20-80 years). Of the cases examined, 42.2% had stage III and 57.8% had stage IV disease. Furthermore, 62.5, 19.7, 9.2, 5.2, and 3.4% had performance statuses of 0, 1, 2, 3, and 4, respectively. The 5-year OS was 91.2%, and no survival plateau was observed. Seventeen patients experienced secondary malignancies (six hematological diseases and 11 solid cancers; 5-year probability, 4.2%). Eighteen patients experienced transformation (5-year probability, 4.5%). The overall survival at 5 years after therapy for transformation was 50%. Before the introduction of rituximab, the 5- to 10-year OS of advanced-stage FL patients in Japan was reported to be about 30-60%. Although these data are limited, improvement in OS has been observed in Japan during the rituximab era.
authors: Department of Hematology Oncology, Higashi Sapporo Hospital, Sapporo, Japan, hirayama@hsh.or.jp.
authors: Yasuo
authors: Y
authors: Hirayama
authors: Kunihiko
authors: K
authors: Ishitani
authors: Shuithi
authors: S
authors: Ota
authors: Mitsutoshi
authors: M
authors: Kurosawa
authors: Takeshi
authors: T
authors: Kondo
authors: Rishu
authors: R
authors: Takimoto
authors: Akio
authors: A
authors: Mori
authors: Hajime
authors: H
authors: Sakai
authors: Yoshihiro
authors: Y
authors: Torimoto
authors: Satoshi
authors: S
authors: Yamamoto
authors: Kazuya
authors: K
authors: Sato
authors: Hiroshi
authors: H
authors: Iwasaki
authors: Kyuhei
authors: K
authors: Kohda
authors: Tadao
authors: T
authors: Ishida
authors: Yasuhiro
authors: Y
authors: Kakinoki
authors: Takashi
authors: T
authors: Fukuhara
authors: Junji
authors: J
authors: Kato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D054338:Cell Transdifferentiation; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D007564:Japan; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab